Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Long-Term Investments (2019 - 2025)

BridgeBio Pharma's Long-Term Investments history spans 5 years, with the latest figure at $92.2 million for Q3 2025.

  • For Q3 2025, Long-Term Investments fell 42.55% year-over-year to $92.2 million; the TTM value through Sep 2025 reached $92.2 million, down 42.55%, while the annual FY2024 figure was $143.7 million, N/A changed from the prior year.
  • Long-Term Investments for Q3 2025 was $92.2 million at BridgeBio Pharma, down from $108.0 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $160.4 million in Q3 2024 and bottomed at $60.7 million in Q2 2021.
  • The 3-year median for Long-Term Investments is $112.5 million (2024), against an average of $111.6 million.
  • The largest annual shift saw Long-Term Investments soared 254.17% in 2021 before it plummeted 42.55% in 2025.
  • A 3-year view of Long-Term Investments shows it stood at $60.7 million in 2021, then soared by 136.86% to $143.7 million in 2024, then crashed by 35.88% to $92.2 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Long-Term Investments are $92.2 million (Q3 2025), $108.0 million (Q2 2025), and $128.2 million (Q1 2025).